Camlin Fine Sciences Q2FY26 Concall Decoded: When Tariffs Meet Chemistry—Margins Melt!
1. Opening Hook
When global trade wars meet aroma chemicals, even vanilla starts smelling like trouble. Camlin Fine Sciences (CFS) entered Q2FY26 juggling tariffs, price pressure, and Europe’s mood swings. Yet, the management claims they’ve whipped up growth out of thin air (and maybe a few new blends). Their US dreams are tariff-twisted, Europe’s shelves are still overstocked, and China’s dumping vanillin like clearance candy. But wait—acquisitions and 40% volume jumps hint there’s more brewing beneath. Stick around; the blend gets spicier later.
2. At a Glance
Revenue ₹460 Cr (+8.6%) – CFO swears it’s not Excel sorcery, just aromatic momentum.
EBITDA ₹33 Cr (↑73%) – Back from the dead, proving shutdowns aren’t forever.
EBITDA Margin 7.27% – Not Michelin-star margins yet, but hey, better than last quarter’s diet.
Gross Margin 46% (↑200 bps) – Plants finally working like they’re paid to.
Net Profit ~Break-even – Profits are still shy, maybe hiding behind tariffs.
Debt ₹640 Cr (Stable) – Borrowing smells constant; repayments just balancing the karma.
3. Management’s Key Commentary
“Revenue grew 8.6% QoQ, mainly from trades and blends.” (Translation: Straight chemicals dragged their feet; blends saved the day.)
“Vanillin volumes up 35%, but realizations hurt by 50% US tariffs.” (Translation: Sales up, smiles down. Tariffs made vanilla a luxury.)
“Gross margins back at 46%, thanks to Tarapur and Dahej humming smoothly.” (Translation: Machines finally stopped throwing tantrums. 😏)
